Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPL554 (Ensifentrine) add-on to Tiotropium in COPD
NCT03937479Phase 2Completed
- Sponsor
- Verona Pharma
- Start
- May 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ensifentrine in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Verona Pharma. Primary endpoint: Forced Expiratory Volume in 1 Second (Peak) at Week 4. Started May 2019; status: completed.
02
Drugs
ensifentrine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03937479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03937479.